<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405403</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO-13-PC/MARIA</org_study_id>
    <nct_id>NCT02405403</nct_id>
  </id_info>
  <brief_title>Microglial Activation Role In ALS (MARIA)</brief_title>
  <acronym>MARIA</acronym>
  <official_title>Microglial Activation Role In ALS (MARIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroinflammation, characterized in particular by microglia activation, is an essential
      component of Amyotrophic Lateral Sclerosis (ALS) pathogenesis. Translocator Protein (TSPO) is
      recognized as a specific and sensitive biomarker of neuroinflammation, reflecting disease
      activity. An experimental radiopharmaceutical specific of TSPO expression, namely
      [18F]DPA714, allow to quantify this microglial activation using Positon Emission Tomography
      (PET) imaging.

      The purpose of this study is to longitudinally correlate the spatial distribution of
      neuroinflammation with the pro- or anti-inflammatory state of activated microglia cells in
      ALS, in order to evaluate neurotoxic or neuroprotective microglia activity, by complementary
      approaches in 20 ALS patients:

        -  in vitro: measuring concentrations of several pro- and anti-inflammatory cytokines
           secreted by microglial cells in the cerebrospinal fluid (CSF).

        -  in vivo: [18F]DPA714 PET imaging. These assays will be performed in the framework of the
           clinical follow-up of ALS patients, at the diagnosis of ALS disease and 6 months latter.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    It was more difficult than planned to find patients filling inclusion criteria and those which
    corresponded didn't agree to participate
  </why_stopped>
  <start_date type="Anticipated">March 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of cytokines in cerebrospinal fluid (pg/mL)</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fixation and distribution of [18F]DPA-714 (Binding Potential BP)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>amyotrophic lateral sclerosis (ALS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]DPA-714 PET</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]DPA-714 PET</intervention_name>
    <description>[18F]DPA-714 Positron Emission Tomography</description>
    <arm_group_label>amyotrophic lateral sclerosis (ALS)</arm_group_label>
    <other_name>[18F]DPA-714</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Age ≥ 18 years old

          -  Patient with probable or definite sporadic Amyotrophic Lateral Sclerosis (ALS) form
             according to the modified criteria of El Escorial

          -  Treated with riluzole 2 weeks

          -  Evolution less than 18 months

          -  Mini-Mental State Examination (MMS) score ≥ 26 and Frontal Assessment Battery (FAB)
             (normal)

          -  Affiliated to a social security system

        Exclusion Criteria:

          -  Another unbalanced progressive pathology

          -  Vascular diseases (hypertension, diabetes, smoking, dyslipidemia) unbalanced

          -  Forced vital capacity &lt;75%

          -  Weight loss&gt; 10% of the weight before disease

          -  Status &quot;low affinity binder&quot; or &quot;mixed affinity binder&quot;, the TSPO respect to the [18
             F] DPA-714, which can interfere with the process of neuroinflammation: drugs with
             anti-inflammatory drugs (NSAIDs, corticosteroids, azathioprine, anti-tumor necrosis
             factor (TNF), antibiotics)

          -  Benzodiazepine in the week before the PET scan [18F] DPA-714 given the potential
             consequences for TSPO receivers

          -  Contraindications to MRI in patients with:

               1. Metallic foreign body eye.

               2. Any implanted electronic medical irremovably (pacemaker, neurostimulator,
                  cochlear implants ...)

               3. Metal heart valve,

               4. Vascular clips formerly located on cranial aneurysm.

          -  Treatment in the month before the PET scan [18F] DPA-714 antagonist
             N-methyl-D-aspartate (NMDA) (memantine)

          -  Pregnant women, lactating women, and women in age for procreation and without reliable
             contraception or without history of hysterectomy

          -  ◦Person under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe CORCIA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Corcia P, Valdmanis P, Millecamps S, Lionnet C, Blasco H, Mouzat K, Daoud H, Belzil V, Morales R, Pageot N, Danel-Brunaud V, Vandenberghe N, Pradat PF, Couratier P, Salachas F, Lumbroso S, Rouleau GA, Meininger V, Camu W. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology. 2012 May 8;78(19):1519-26. doi: 10.1212/WNL.0b013e3182553c88. Epub 2012 Apr 25.</citation>
    <PMID>22539580</PMID>
  </results_reference>
  <results_reference>
    <citation>Blasco H, Corcia P, Moreau C, Veau S, Fournier C, Vourc'h P, Emond P, Gordon P, Pradat PF, Praline J, Devos D, Nadal-Desbarats L, Andres CR. 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One. 2010 Oct 8;5(10):e13223. doi: 10.1371/journal.pone.0013223.</citation>
    <PMID>20949041</PMID>
  </results_reference>
  <results_reference>
    <citation>Arlicot N, Vercouillie J, Ribeiro MJ, Tauber C, Venel Y, Baulieu JL, Maia S, Corcia P, Stabin MG, Reynolds A, Kassiou M, Guilloteau D. Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nucl Med Biol. 2012 May;39(4):570-8. doi: 10.1016/j.nucmedbio.2011.10.012. Epub 2011 Dec 14.</citation>
    <PMID>22172392</PMID>
  </results_reference>
  <results_reference>
    <citation>Corcia P, Ingre C, Blasco H, Press R, Praline J, Antar C, Veyrat-Durebex C, Guettard YO, Camu W, Andersen PM, Vourc'h P, Andres CR. Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. Eur J Hum Genet. 2012 May;20(5):588-91. doi: 10.1038/ejhg.2011.255. Epub 2012 Jan 25.</citation>
    <PMID>22274580</PMID>
  </results_reference>
  <results_reference>
    <citation>Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, Nicolas G, Venel Y, Hommet C, Baulieu JL, Cottier JP, Roussel C, Kassiou M, Guilloteau D, Ribeiro MJ. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7(12):e52941. doi: 10.1371/journal.pone.0052941. Epub 2012 Dec 31.</citation>
    <PMID>23300829</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis disease</keyword>
  <keyword>PET</keyword>
  <keyword>microglial activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

